Metastatic renal cell carcinoma (mRCC)

SUTENT® (sunitinib malate) is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (mRCC) in adults.1

1. SUTENT® Summary of Product Characteristics. Pfizer. Available at: https://www.medicines.org.uk/emc/product/227/smpc
PP-SUT-GBR-0620 July 2020